What have long-term registries taught us about the effects of treatment on mitigating risk and/or progression of target organ deterioration—in particular, of cardiac disease, need for kidney replacement, and/or stroke—in patients with FD?

What have long-term registries taught us about the effects of treatment on mitigating risk and/or progression of target organ deterioration—in particular, of cardiac disease, need for kidney replacement, and/or stroke—in patients with FD?

What have long-term registries taught us about the effects of treatment on mitigating risk and/or progression of target organ deterioration—in particular, of cardiac disease, need for kidney replacement, and/or stroke—in patients with FD?


Created by

CMEducation Resources IQ&A Fabry Disease Diagnostic Intelligence Zone

Presenter

Robert Hopkin

Robert Hopkin

Associate Professor of Clinical Pediatrics
Cincinnati Children's Hospital Medical Center
Co-Director, 22Q-VCFS Center
University of Cincinnati College of Medicine
Cincinnati, OH